Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.
about
H5N1 viruses and vaccinesLive, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferretsVaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy adultsExpression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture.H5N1 vaccines in humansA consensus-hemagglutinin-based vaccine delivered by an attenuated Salmonella mutant protects chickens against heterologous H7N1 influenza virus.Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Development of live attenuated influenza vaccines against pandemic influenza strains.Clinical vaccine development for H5N1 influenza.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetA consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesModel answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningDeveloping vaccines against pandemic influenzaDNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.Control of influenza virus infection by immunity to conserved viral features.Influenza: lessons from past pandemics, warnings from current incidents.Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.Vaccines for pandemic influenzaExpression of avian influenza virus (H5N1) hemagglutinin and matrix protein 1 in Pichia pastoris and evaluation of their immunogenicity in mice.A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.Clinical evaluation of vaccines for pandemic influenza H5N1.Avian influenza virus (H5N1): a threat to human health.Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.Pandemic H5N1 influenza vaccine development: an update.Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infectionImmunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.Development of a vaccine against pandemic influenza viruses: current status and perspectives.Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx moriInduction of long-term protective immune responses by influenza H5N1 virus-like particles.Vaccines for an influenza pandemic: scientific and political challenges.
P2860
Q21131612-8F9374DC-F2BB-42E9-B63E-12E7DCBA03C3Q21563426-C24503AB-3DA8-4BB9-96D4-2BA7B9F7613FQ24197955-C3F32592-3BE6-4497-B6BB-4B1E7CA17527Q24234114-5777DCE9-D846-48DA-9BF1-C00D4796C1C6Q24245429-A618A295-ABED-43C3-963C-146ACB712E66Q25257105-91ADA3A8-4ED5-4E4E-A6B0-C370E0710C1EQ27000896-3FAFF846-3F4D-4B85-82E9-B44A262ABE68Q30148715-3CE2B951-81A5-4093-8CE7-08BFCA518AA5Q30204573-91A93594-D50C-4747-AAAD-D31F51CF4D77Q30204578-EBFDCE43-B38E-4EA3-88E5-EDCC5D6F52C9Q30209998-B59C6924-58C5-46B3-A23B-1F9F3E12381BQ30222083-94BF56C5-5290-4CEF-BDF5-D9F410656E15Q30227194-7E39C8EB-2665-4376-9CBD-623B58610CEBQ30228657-E78042AD-2AEE-477B-B521-64C765055FA3Q30230076-14A67F15-1ECD-467A-9445-78F647B00A6CQ30329367-3ADA07D2-85A0-41EB-BB03-6274AC11D9F7Q30331219-8BFDEBE8-2F49-48B5-AEC2-FF2ED3F19BB4Q30343902-BC2E9563-223B-4D2C-9C71-A3916795ED9DQ30351160-00FFFDD1-C0FC-482E-8454-6F9C0FA9B4DFQ30352927-9D4D5E32-3DB8-4E48-B3C0-959463127E4FQ30353073-F3BD9436-DECB-45F6-9811-DA86C7C96B05Q30359355-D475F95B-79FF-4CA2-B29B-B447C1FA41AAQ30359896-1F697193-BB48-4F44-B561-D4E1F4E8E7ECQ30360545-E71A599D-DA67-4C97-93B8-204765DA1A68Q30361041-B558DEA4-14B6-4CB3-813F-F3E7A23CE5B8Q30361581-6C09403A-D841-415B-A09D-9DEA67C71BCDQ30362794-CF7A776A-BC3B-4AB0-9A25-ACAC1FB0CB0AQ30362811-7D446080-1C71-4EBF-8F3F-E2656C047300Q30365380-C56DAE9E-8417-4B0D-97E1-5681DEB26DD5Q30366806-9ABEF413-5A2F-41B0-97C9-5427480431FBQ30368132-06E8336D-8DF4-445C-AC06-5314A42C3A81Q30368474-4A4D242F-D47E-4004-A8E4-92C8FEE718AFQ30369679-64BDF949-7C7D-41F1-9A86-3389F1D588C1Q30371674-C5774FD2-9A35-48F6-886D-F69F1A03D621Q30372167-ED8FC4F0-8AA2-45CB-8A55-17727EC4B8FCQ30372964-5225F3FA-9F3A-4209-A96C-A2D5D76C96E2Q30373784-FC2F4790-DEF9-4471-9B1E-20E65C3DC4ADQ30373913-637B6F93-4100-4B83-847A-4B6A67DC1CB1Q30375255-03B709D8-BE3A-4588-BB00-1FAC093BEBE3Q30376971-AA137D05-9E2F-4481-8208-48E38C466119
P2860
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@ast
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@en
type
label
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@ast
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@en
prefLabel
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@ast
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@en
P2093
P1433
P1476
Safety and immunogenicity of a ...... ne for H5 influenza in humans.
@en
P2093
Battaglia R
Blackwelder W
Hu-Primmer J
Masseoud F
Rabinovich G
Treanor JJ
Wilkinson BE
P304
P356
10.1016/S0264-410X(00)00395-9
P407
P577
2001-02-01T00:00:00Z